ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

With the prevalence of diabetes quadrupling in recent decades and currently impacting more than 500 million people in the world, it is no surprise that the technology for insulin delivery has also ...

The dream of a completely closed-loop system for diabetes management is now closer than ever for many Type 1 diabetes patients, thanks to the widespread U.S. launch of a completely automated, ...

Just a few weeks into the full-scale rollout of its Omnipod 5 insulin pump, Insulet has gotten the green light to expand the device’s reach even further. When the FDA originally cleared the automated, ...

New insulin pod is expected to launch at the end of August for type 1 diabetes. These pods are expected to cost $800 for two months worth of supply. A new device is set to launch early this coming ...

Insulin pumps are the most advanced insulin delivery technology available today for people with type 1 and type 2 diabetes. An insulin pump replaces injections with a syringe or insulin pen, using an ...

“As part of our ongoing efforts to bring Omnipod technology to more people living with diabetes around the world, we’re excited to announce that Omnipod DASH will soon be available in Australia,” said ...

Medtronic has recalled some of its insulin pumps after injuries and one death were reported due to the device malfunctioning, according to a US Food and Drug Administration announcement on Wednesday.

The Omnipod 5 will be immediately available for people ages 6 to 70. A new technology for people with Type 1 diabetes, one that has been nearly a decade in the making, has been approved by the U.S.